Cargando…

Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1

BACKGROUND: Mounting evidence supports that long noncoding RNAs (lncRNAs) have critical roles during cancer initiation and progression. In this study, we report that the plasmacytoma variant translocation 1 (PVT1) lncRNA is involved in breast cancer progression. METHODS: qRT-PCR and western blot wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuiyi, Chen, Weiqun, Hu, Hui, Zhang, Tianzhu, Wu, Tangwei, Li, Xiaoyi, Li, Yong, Kong, Qinzhi, Lu, Hongda, Lu, Zhongxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684126/
https://www.ncbi.nlm.nih.gov/pubmed/34922601
http://dx.doi.org/10.1186/s13058-021-01491-y
Descripción
Sumario:BACKGROUND: Mounting evidence supports that long noncoding RNAs (lncRNAs) have critical roles during cancer initiation and progression. In this study, we report that the plasmacytoma variant translocation 1 (PVT1) lncRNA is involved in breast cancer progression. METHODS: qRT-PCR and western blot were performed to detect the gene and protein expression. Colony formation would healing and transwell assays were used to detect cell function. Dual-luciferase reporter assay and RNA pull-down experiments were used to examine the mechanisms interaction between molecules. Orthotopic mouse models were established to evaluate the influence of PVT1 on tumor growth and metastasis in vivo. RESULTS: PVT1 is significant upregulated in breast cancer patients’ plasma and cell lines. PVT1 promotes breast cancer cell proliferation and metastasis both in vitro and in vivo. Mechanistically, PVT1 upregulates FOXQ1 via miR-128-3p and promotes epithelial–mesenchymal transition. In addition, PVT1 binds to the UPF1 protein, thereby inducing epithelial–mesenchymal transition, proliferation and metastasis in breast cancer cells. CONCLUSION: PVT1 may act as an oncogene in breast cancer through binding miR-128-3p and UPF1 and represents a potential target for BC therapeutic development. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-021-01491-y.